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DISCUSSION 
L . P . de W a a l , Rapporteur 
T a u r o g reported on disease susceptibility of HLA-B27-transgenic rats. He has observed 
the spontaneous development of peripheral arthritis in the majority of male rats in one of 
five lines of transgenic Lewis rats bearing the HLA-B2705 and human ß 2-microglobulin 
genes. The arthritis was associated clinically with diarrhoea and histologically with a 
diffuse mononuclear cell inflammatory infiltrate in the gastrointestinal tract and with 
synovial pannus formation. Unfortunateiy, there were no animals expressing a control 
H L A class-I antigen. 
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ABSTRACT 
In order to develop a possible animal model to study H L A linked diseases of man, we 
established HLA-B27 transgenic mice (TGM). As aberrant and overexpression of M H C 
molecules can be toxic for cells, we aimed at obtaining a physiological expression of the 
human antigen and used a genomic 25kb Sal I fragment for embryo injection, coding for 
the H L A - B * 2705 heavy chain. Five independent founder mice were obtained containing 
varying copies of the fragment (1 to 10). R N A analysis from different tissues showed an 
expression pattern similar to endogenous H-2 class I genes. HLA-B27 antigen could be 
detected on lymphocytes derived from all five founder mice, even in the absence of human 
ß 2-microglobulin (huß2m). It was found that the presence of huß2m strongly enhances 
HLA-B27 cell surface expression in mice with few copies of the transgene, but was not 
necessary for efficient and high cell surface presentation in the 10 copy line. In all H L A -
B27 T G M lines, the H L A molecule functions as restriction element in anti-viral responses. 
In addition, we could show that T lymphocytes of the transgenic animals respond to the 
same HLA-B27 restricted influenza peptide as is recognized by human influenza-specific, 
HLA-B27 restricted cytotoxic T cell lines. 
Key w o r d s : HLA-B27 transgenic mice, virus-specific cytotoxic T cell, peptide recognition. 
INTRODUCTION 
Because of the disease association of the human HLA-B27 antigen with ankylosing 
Spondylitis and reactive arthritis, several groups started to generate HLA-B27 transgenic 
mice (TGM), in order to obtain an animal model for the HLA-B27 linked diseases in man 
(1, 2, 3, 4). The availability of HLA-B27-TGM might allow the study of its receptor 
function for viral and microbial peptides and the identification of potential enterobacterial, 
cross-reactive epitopes. We took advantage of our HLA-B27 cosmid clone cd2.6 (5) and 
used a 25 kb Sal I fragment for microinjection into outbred NMRI mice. We aimed at the 
Integration of few copies of the transgene in order to obtain a physiological expression of 
the human class I restriction element. Conflicting results have been obtained in respect of 
the frequency of cytotoxic precursors in H L A class I T G M that could utilize the transgene 
product as restriction element (6, 7, 8, 9). Only one group has shown that either the H L A -
Cw3 or the HLA-B27*2702 transgene can be efficiently used as restriction element for 
influenza or Sendai virus-specific cytotoxic T lymphocytes (CTL) (10, 1, 3). These 
experiments have been performed with two T G M lines, which have not been well charac-
terized with regard to the integrated copy number of the transgene and quantitative cell 
surface expression. It was therefore of interest to investigate whether our five independent 
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lines of HLA-B*2705 transgenic mice containing one up to 10 copies would generate an 
anti-viral HLA-B27 restricted cytotoxic response. 
Moreover, in order for H L A - T G M to present an animal model for human autoimmune 
diseases, it is requested that T cells of the T G M use the human restriction element in a 
fashion similar to human T lymphocytes. We asked the important question whether T cells 
of the HLA-B27-TGM recognize the same viral peptide ligand in context with HLA-B27 as 
human B27 + T effector cells. We found that B27 + -TGM T lymphocytes respond to the 
same HLA-B27 restricted influenza peptide as has been reported for human influenza-
specific, HLA-B27 restricted cytotoxic T cells (11). 
MATERIALS A N D M E T H O D S 
A 25 kb Sal I fragment of the HLA-B*2705 genomic clone cd2.6 (5) was used to generate 
transgenic mice (4, 12). Screening of the progeny was performed by the isolation of tail 
DNA by Proteinase K digestion. 20 u.g of EcoRI restricted D N A was electrophoresed on 
0.7% agarose gels and transferred to nylon membrane. Hybridization with the 6.7 kb 
HLA-B27 EcoRI fragment was performed as described previously (13). 
I n d i r e c t immunofluorescence 
Total spieen or lymphnode cells were isolated and suspended in RPMI 1640/5 % FCS. 1 x 106 
lymphocytes were stained with supernatants of the following monoclonal antibodies: TM5 
(mouse anti-HLA class I, 14) B B M . l (mouse anti-human 02m; ATCC), and Ml/42.3.9.8 
(rat anti-H-2 class I; ATCC). Antibody TM5 recognizes H L A class I heavy chains 
regardless of the origin of ßlm (14). For cytofluorometric analyses (FACSan, Becton 
Dickenson), lymphocytes were stained with first antibodies and subsequently incubated 
with FITC labeled goat anti-mouse IgG or mouse anti-rat IgG. 
Generation and assay o f C T L 
Virus specific CTLs were generated and analysed as described (1, 3). Briefly, transgenic 
mice were immunized in vivo by i.p. injection of 1000 H A U of influenza virus A7X79 in 
500 ui of PBS. Twenty days after priming, spieen cells were stimulated in vitro with equal 
numbers of virus infected and irradiated (25 GY) autologous spieen cells. After 5 days, 
CTLs were assayed in a 4-hr 51Cr-release test on various target cells, either uninfected, or 
influenza infected or coated with influenza derived peptides. Infection of target lymphnode 
cells was started 3 hrs prior labeling, or target cells were either incubated with an H L A -
B27 restricted influenza peptide derived from the nucleoprotein (NP) recognized by human 
influenza specific HLA-B27 restricted C T L (11) or with an H-2D b restricted NP peptide 
recognized by mouse influenza specific H-2D b restricted C T L (15) at two concentrations 
0.1 mg/ml and 0.01 mg/ml. 
RESULTS 
Generation of H L A - B 2 7 transgenic mice 
A 25 kb Sal I fragment of the HLA-B*2705 cosmid clone cd2.6 (Fig. 1) was used to 
generate transgenic mice. This fragment covers the complete 4.3 kb HLA-B27 gene as well 
as its 7 kb 5' and 14 kb 3' flanking regions. Five independent HLA-B27 founder mice were 
obtained with one Integration site each. The copy number ranged from 1 to 10 per cell. 
Two founder mice (865-11; 864-12) carried only one copy, whereas the other ones con-
tained two copies (865-1), four copies (854-8) and ten copies (875-5), respectively. 
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F i g . 1 . The Organization of the transgenic HLA-B27 Sal I fragment. The 25 kb Sal I fragment coding for the H L A -
B*2705 antigen (middle line) is contained within the cosmid cd2.6 (top line, 1). On the bottom is shown the enlarged 
HLA-B27 gene as 6.7 kb EcoRI fragment. Ciosed boxes indicate the protein coding exons (1-7), and the open box 
shows the extent of the 3' untranslated region. The Bgl II and the Pst I sites are only given for the EcoRI fragment. 
c <D ü 
J2 
O 
10i 
10! 
Om 
A 
A 
v > 
4 
I 
10 
F i g . 2. Copy number and the presence of human /?2-imcroglobulin control cell surface expression of 
the human class I heavy chain in HLA-B27-TGM. Lymphocytes of the different T G M lines (1, 2, 4, 
and 10 copies) and of non-transgenic littermate were stained with the anti-HLA-class I monoclonal 
antibody TM5 (triangles) or the anti H-2-class I monoclonal antibody 42.3.9.8 (circles). The relative 
logio fluorescence (ordinate) is compared with the integrated HLA-B27 gene copy number of the 
individual lines (abscissa). Each symbol presents surface fluorescence of one mouse: open symbols, 
HLA-B27-TGM; Closed symbols, HLA-B27/hu/?2m-TGM. 
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influenza virus X79 influenza NP peptide 
:1 
F i g . 3. HLA-B27 serves as restriction element for virus specific cytotoxic T lymphocytes in H L A -
B27-TGM. Left: Lysis of influenza virus infected (circles) and uninfected (Squares) lymphocytes of 
HLA-B27-TGM (open symbols) or non-transgenic littermate (closed symbols) of influenza specific 
CTL, measured with increasing effector to target cell ratios (abscissa) in a Cr release assay (ordinate). 
R i g h t : Target cells were either coated with a NP peptide restricted to HLA-B27 (0/#, 0.1 mg/ml; • , 
0.01 mg/ml) or with a NP peptide restricted to H-2D b ( A / A , 0.1 mg/ml). 
Tissue specific expression 
To investigate tissue specific expression of the HLA-B27 transgene, RNA from spieen, 
liver, kidney, thymus and brain was analysed from offspring of each line by Northern blot 
hybridization with the H L A - B specific (13) and an H-2 class I specific probe (4). In all 
cases the tissue specificity of expression is concordant with that of the relevant endog-
enous mouse genes except in the liver, where relative low levels of HLA-B27 mRNA were 
detected. We found the same expression pattern in human tissues with little HLA-class I 
transcripts in human liver (12). Transcription in one-copy mice was approximately ten 
times lower than in ten-copy mice. The latter showed an H L A mRNA level similar to that 
of the human B cell line LG2. 
C e l l surface expression of H L A - B 2 7 i n transgenic mice 
We analyzed all T G M lines for cell surface expression of the HLA-B27 heavy chain on 
splenocytes and lymph node cells. We found that all T G M lines express the HLA-B27 
antigen on the cell surface (Fig. 2). The amount detected on lymphocytes correlated with 
the HLA-B27 gene copy number. Even mice containing only one HLA-B27 gene, could be 
stained with anti H L A class I reagents. Coexpression of human ß2m increases cell surface 
expression of the HLA-B27 heavy chain. AU T G M founder mice were backcrossed to 
hu/?2m-TGM, and singly and doubly transgenic offspring were analysed by FACS (Fig. 2). 
The level of HLA-B27 cell surface fluorescence was 5-10 times greater for lymphocytes 
from doubly transgenic mice. Only the presence of hu/?2m allowed efficient cell surface 
representation of HLA-B27 in T G M expressing HLA-B27 mRNA at the same relative 
level as endogenous H-2 class I. T G M containing 10 copies of the transgene, had as much 
HLA-B27 molecules on the cell surface as mouse H-2 class I antigen. 
Scand J Rheumatology Suppl 87 H L A class-l-transgenic mice as model System 95 
I m m u n o l o g i c a l functions o f H L A - B 2 7 i n transgenic mice 
The availability of HLA-B27-TGM allowed us to investigate the immunological function of 
a Single H L A class I restriction element in isolation from the complexity of the human 
MHC. We could show that our HLA-B27-TGM carrying the HLA-B*2705 subtype were 
capable of using the HLA-B27 antigen as a restriction element for virus-specific T cell 
responses (4, and Fig. 3). As this is the case, we then addressed the question whether the 
T G M T cell repertoire recognizes similar peptides in context with the HLA-B27 antigen as 
human T lymphocytes (11). We tested anti-viral C T L obtained from 854-8/hu/32m-TGM 
after priming with influenza X79 virus in vivo, for recognition of the HLA-B27 restricted 
NP peptide. We could show that the anti-viral C T L also lyse lymphocytes of HLA-B27-
T G M coated with the specific NP peptide. No lysis was observed with peptide coated cells 
of non-transgenic mice or when incubated with a control peptide (Fig. 3). 
DISCUSSION 
Although several groups described HLA-class I transgenic mice, the HLA-B27-TGM lines 
obtained with the 25 kb Sal I fragment are unique. First, in all lines we could detect the 
transgenic molecule by staining with a variety of anti-HLA-class I monoclonal antibodies. 
To our knowledge, no other T G M lines with one or few HLA-class I gene copies 
integrated, have been reported to show cell surface expression of the transgene (2, 16, 17). 
In addition, only the HLA-B27-TGM lines described here, show a level of transgene 
expression which increases with the number of integrated HLA-B27 copies. Perhaps 
sequences flanking the HLA-B27 gene are necessary for efficient, copy-number depend-
ent, Integration site independent transcription of the H L A - B gene (16). We also show that 
the frequency of cytotoxic precursors that utilize the HLA-B*2705 molecule as restriction 
element is rather high in all five HLA-B27-TGM lines and can be detected in bulk cultures, 
similar to the results obtained with a HLA-B*2702 and a HLA-Cw3-TGM line (1, 10). The 
reason why the HLA-A2 and HLA-B7-TGM fail to show a good HLA-restricted virus 
response is not clear yet. In addition, we found that T G M T lymphocytes respond to the 
same HLA-B27 restricted influenza peptide as human influenza-specific, HLA-B27 re-
stricted cytotoxic T cells. This result indicates that the major epitope recognized by H L A -
B27 restricted influenza specific C T L is not altered by species-specific differences in the T 
cell repertoire. In conclusion, our results demonstrate the Utility of HLA-B27-TGM to 
define pathogen-specific epitopes presented by the HLA-B27 antigen. Moreover, they 
encourage the hope that mice transgenic for HLA-B27 may contribute towards establish-
ing a model System for HLA-B27 associated disease studies. 
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